05 July 2022>: Clinical Research
A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania
Xenia Bacinschi 1E , Gabriel Cristian Popescu 2C , Anca Zgura 1C* , Laurentia Gales 1F , Anghel Rodica 1A , Adriana Mercan 3D , Dragos Serban 4D , Bogdan Haineala 5B , Letitia Toma 3C , Laura Iliescu 3FDOI: 10.12659/MSM.936706
Med Sci Monit 2022; 28:e936706
Table 2 Common adverse reactions in the study groups.
Total group (N=587 patients) | Without ribavirin (n=343 patients) | With ribavirin (n=245 patients) | Chi-square | |
---|---|---|---|---|
Asthenia | 178 patients (30.32%) | 56 patients (16.37%) | 112 patients (49.79%) | −0.52 |
Nausea | 213 patients (36.28%) | 98 patients (28.57%) | 115 patients (46.93%) | −0.47 |
Headaches | 132 patients (22.48%) | 43 patients (12.53%) | 89 patients (36.32%) | −0.33 |